Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Retained Earnings (2016 - 2025)

Collegium Pharmaceutical has reported Retained Earnings over the past 10 years, most recently at $319000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at $319000.0 for Q4 2025, up 480.0% from a year ago — trailing twelve months through Dec 2025 was $319000.0 (up 480.0% YoY), and the annual figure for FY2025 was $319000.0, up 480.0%.
  • Retained Earnings for Q4 2025 was $319000.0 at Collegium Pharmaceutical, up from $292000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for COLL hit a ceiling of $337000.0 in Q2 2025 and a floor of -$312.2 million in Q1 2021.
  • Median Retained Earnings over the past 5 years was -$181.2 million (2024), compared with a mean of -$139.9 million.
  • Biggest five-year swings in Retained Earnings: plummeted 489031.58% in 2024 and later soared 480.0% in 2025.
  • Collegium Pharmaceutical's Retained Earnings stood at -$256.3 million in 2021, then fell by 9.75% to -$281.3 million in 2022, then soared by 100.0% to $14000.0 in 2023, then soared by 292.86% to $55000.0 in 2024, then soared by 480.0% to $319000.0 in 2025.
  • The last three reported values for Retained Earnings were $319000.0 (Q4 2025), $292000.0 (Q3 2025), and $337000.0 (Q2 2025) per Business Quant data.